Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
8 evidence topics · 7 sources
REVEAL Part A: response across age, disease severity, and genotype
REVEAL Part A: response by dose cohort
Published review: dose response in the first REVEAL cohorts
MECP2 variant: genotype coverage of the miniMECP2 transgene
“By delivering the essential MBD and NID functional domains, TSHA-102 provides a genotype-agnostic approach that encompasses the molecular defects found in over 95% of the RTT population, including the eight most common recurrent mutations and nearly all pathogenic missense variants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MECP2 variant and X-chromosome inactivation: sources of variation in disease severity
“Thus, we have confirmed that MECP2 mutation type is a strong predictor of disease severity. However, clinical severity continues to become progressively worse with advancing age regardless of initial severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because the MECP2 gene is subject to X‐chromosome inactivation (XCI), factors including MECP2 genotypic variation, tissue differences in XCI, and skewing of XCI all likely contribute to the clinical severity of individuals with RTT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at treatment: developmental window
“Nonetheless, several considerations favor earlier intervention: the first 2–3 years of life represent critical windows of synaptogenesis and circuit formation; prolonged MeCP2 deficiency may lead to structural neuronal and glial changes that become harder to reverse; and treating before or during early regression could prevent milestone loss rather than requiring later recovery (83, 84).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ultimately, a stratified approach may emerge in which early treatment maximizes developmental potential while older individuals are treated to achieve meaningful functional gains.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote